Literature DB >> 25801563

In vivo antimalarial activity and mechanisms of action of 4-nerolidylcatechol derivatives.

Luiz Francisco Rocha e Silva1, Karla Lagos Nogueira2, Ana Cristina da Silva Pinto3, Alejandro Miguel Katzin4, Rodrigo A C Sussmann4, Magno Perêa Muniz3, Valter Ferreira de Andrade Neto5, Francisco Célio Maia Chaves6, Julia Penna Coutinho7, Emerson Silva Lima8, Antoniana Ursine Krettli7, Wanderli Pedro Tadei3, Adrian Martin Pohlit9.   

Abstract

4-Nerolidylcatechol (1) is an abundant antiplasmodial metabolite that is isolated from Piper peltatum roots. O-Acylation or O-alkylation of compound 1 provides derivatives exhibiting improved stability and significant in vitro antiplasmodial activity. The aim of this work was to study the in vitro inhibition of hemozoin formation, inhibition of isoprenoid biosynthesis in Plasmodium falciparum cultures, and in vivo antimalarial activity of several 4-nerolidylcatechol derivatives. 1,2-O,O-Diacetyl-4-nerolidylcatechol (2) inhibited in vitro hemozoin formation by up to 50%. In metabolic labeling studies using [1-(n)-(3)H]geranylgeranyl pyrophosphate, diester 2: significantly inhibited the biosynthesis of isoprenoid metabolites ubiquinone 8, menaquinone 4, and dolichol 12 in cultures of P. falciparum 3D7. Similarly, 2-O-benzyl-4-nerolidylcatechol (3) significantly inhibited the biosynthesis of dolichol 12. P. falciparum in vitro protein synthesis was not affected by compounds 2 or 3. At oral doses of 50 mg per kg of body weight per day, compound 2 suppressed Plasmodium berghei NK65 in infected BALB/c mice by 44%. This in vivo result for derivative 2 represents marked improvement over that obtained previously for natural product 1. Compound 2 was not detected in mouse blood 1 h after oral ingestion or in mixtures with mouse blood/blood plasma in vitro. However, it was detected after in vitro contact with human blood or blood plasma. Derivatives of 4-nerolidylcatechol exhibit parasite-specific modes of action, such as inhibition of isoprenoid biosynthesis and inhibition of hemozoin formation, and they therefore merit further investigation for their antimalarial potential.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25801563      PMCID: PMC4432218          DOI: 10.1128/AAC.05012-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  50 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

2.  Drug resistance in Plasmodium berghei Vincke and Lips, 1948. I. Chloroquine resistance.

Authors:  W Peters
Journal:  Exp Parasitol       Date:  1965-08       Impact factor: 2.011

3.  Drug sensitivity of plasmodium falciparum. An in-vitro microtechnique.

Authors:  K H Rieckmann; G H Campbell; L J Sax; J E Mrema
Journal:  Lancet       Date:  1978-01-07       Impact factor: 79.321

Review 4.  The potential of secondary metabolites from plants as drugs or leads against protozoan neglected diseases - part I.

Authors:  T J Schmidt; S A Khalid; A J Romanha; T Ma Alves; M W Biavatti; R Brun; F B Da Costa; S L de Castro; V F Ferreira; M V G de Lacerda; J H G Lago; L L Leon; N P Lopes; R C das Neves Amorim; M Niehues; I V Ogungbe; A M Pohlit; M T Scotti; W N Setzer; M de N C Soeiro; M Steindel; A G Tempone
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 5.  Malaria biology and disease pathogenesis: insights for new treatments.

Authors:  Louis H Miller; Hans C Ackerman; Xin-zhuan Su; Thomas E Wellems
Journal:  Nat Med       Date:  2013-02-06       Impact factor: 53.440

6.  Human malaria parasites in continuous culture.

Authors:  W Trager; J B Jensen
Journal:  Science       Date:  1976-08-20       Impact factor: 47.728

7.  Synchronization of Plasmodium falciparum erythrocytic stages in culture.

Authors:  C Lambros; J P Vanderberg
Journal:  J Parasitol       Date:  1979-06       Impact factor: 1.276

8.  Terpenes arrest parasite development and inhibit biosynthesis of isoprenoids in Plasmodium falciparum.

Authors:  Herbert Rodrigues Goulart; Emília A Kimura; Valnice J Peres; Alicia S Couto; Fulgencio A Aquino Duarte; Alejandro M Katzin
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

9.  Potent in vivo anti-malarial activity and representative snapshot pharmacokinetic evaluation of artemisinin-quinoline hybrids.

Authors:  Marli C Lombard; David D N'Da; Christophe Tran Van Ba; Sharon Wein; Jennifer Norman; Lubbe Wiesner; Henri Vial
Journal:  Malar J       Date:  2013-02-21       Impact factor: 2.979

10.  Stability and antioxidant activity of semi-synthetic derivatives of 4-nerolidylcatechol.

Authors:  Emerson Silva Lima; Ana Cristina Silva Pinto; Karla Lagos Nogueira; Luiz Francisco Rocha e Silva; Patricia Danielle Oliveira de Almeida; Marne Carvalho de Vasconcellos; Francisco Celio Maia Chaves; Wanderli Pedro Tadei; Adrian Martin Pohlit
Journal:  Molecules       Date:  2012-12-24       Impact factor: 4.411

View more
  3 in total

1.  Synthesis, antiplasmodial activity and in silico molecular docking study of pinocembrin and its analogs.

Authors:  Yadessa Melaku; Melat Solomon; Rajalakshmanan Eswaramoorthy; Uwe Beifuss; Vladimir Ondrus; Yalemtsehay Mekonnen
Journal:  BMC Chem       Date:  2022-05-24

2.  Poly-ε-caprolactone Nanoparticles Loaded with 4-Nerolidylcatechol (4-NC) for Growth Inhibition of Microsporum canis.

Authors:  Vanessa Raquel Greatti; Fernando Oda; Rodrigo Sorrechia; Bárbara Regina Kapp; Carolina Manzato Seraphim; Ana Carolina Villas Bôas Weckwerth; Marlus Chorilli; Patrícia Bento Da Silva; Josimar O Eloy; Marcelo J Kogan; Javier O Morales; Rosemeire Cristina Linhari Rodrigues Pietro
Journal:  Antibiotics (Basel)       Date:  2020-12-11

3.  Various Parts of Helianthus annuus Plants as New Sources of Antimalarial Drugs.

Authors:  Wiwied Ekasari; Dwi Widya Pratiwi; Zelmira Amanda; Aty Widyawaruyanti; Heny Arwati
Journal:  Evid Based Complement Alternat Med       Date:  2019-11-26       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.